Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Cardiometrics/Cordis

This article was originally published in The Gray Sheet

Executive Summary

Cardiometrics/Cordis: Ink distribution agreement under which Johnson & Johnson subsidiary Cordis gains U.S. distribution rights to Cardiometrics' FloWire doppler guide wire. The pact broadens an existing agreement for marketing of the device overseas. Cardiometrics says J&J's "strong distribution channels should enable faster market penetration" in the U.S. Under the deal, J&J also gains U.S. rights to Cardiometrics' WaveWire pressure guide wire products. Cardiometrics submitted a 510(k) for WaveWire in December 1996. Cardiometrics, which recently entered an agreement to be acquired by intravascular ultrasound catheter firm EndoSonics ("The Gray Sheet" Feb. 3, p. 9), will continue to market its FloWire and WaveWire products domestically to "40 key accounts" through the end of 1997. At year-end, J&J, EndoSonics, and Cardiometrics will negotiate terms for 1998...

You may also be interested in...

Lannett Plans Seven Launches In Fiscal Year 2021

Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020. 

Pfizer Picks Up EU Pegfilgrastim Approval

Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.

A Stroke Of Luck Boosts Oxford/AZ’s “Vaccine For The World”

AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts